Ernexa Therapeutics develops cell therapies for advanced cancer and autoimmune disease using engineered induced pluripotent stem cells that are transformed into synthetic allogeneic induced mesenchymal stem cells. News about the company centers on ERNA-101, its lead iMSC candidate for ovarian cancer, including preclinical tumor-model results, immuno-oncology combinations and scientific discussions of the ovarian cancer treatment landscape.
Company updates also cover ERNA-201 for autoimmune inflammation, regulatory interactions tied to cell-therapy development, investor presentations, collaboration or market-entry programs, and capital-structure actions such as common-stock reverse splits and Nasdaq listing compliance.
Eterna Therapeutics Inc. (Nasdaq: ERNA) has appointed Matt Angel, Ph.D., as its permanent Chief Executive Officer and President, continuing from his role as Interim CEO since May 2022. The Board expressed confidence in his leadership, emphasizing the need to advance Eterna’s mRNA cell engineering platform. Dr. Angel brings extensive experience in biotechnology and a significant patent portfolio, including over 100 patents related to gene editing and mRNA technologies. Eterna focuses on leveraging its in-licensed patent portfolio to drive value in 2023.
Eterna Therapeutics Inc. (Nasdaq: ERNA) has entered into a sponsored research agreement with Dr. Michael Andreeff from MD Anderson Cancer Center to evaluate its gene-edited iPS cell therapeutic candidates. The research aims to enhance T-cell immunity and promote hematopoietic regeneration, potentially accelerating treatments for acute myeloid leukemia and solid tumors. Eterna's mRNA-based cell therapies are noted for their manufacturing consistency. CEO Matt Angel expressed enthusiasm for advancing cancer treatment through this agreement, which is a critical component of Eterna's cancer therapy pipeline.
Eterna Therapeutics Inc. (Nasdaq: ERNA) announced that Dr. Matt Angel, the Interim CEO, will present at the iPSC-Derived Immunotherapies Congress on October 18-19, 2022, in Boston. The presentation, titled "Avoiding Vector Integration Using mRNA Vectorization of Reprogramming and Gene Editing Proteins," is scheduled for October 18, 2022, at 3:10 p.m. ET at the Hilton Boston Back Bay Hotel. Eterna focuses on advanced cell engineering technology to develop new medicines and holds over 100 patents related to cell engineering.
Eterna Therapeutics Inc. (Nasdaq: ERNA) announced an option agreement with Exacis Biotherapeutics to negotiate an exclusive, worldwide license for developing up to four iNK and/or iT cell programs targeting hematologic malignancies and solid tumors. This partnership highlights Exacis' advanced non-viral cell engineering technology, aimed at creating next-generation therapies without the risks associated with viral integration. The agreement must be finalized by December 31, 2022. Eterna has also completed its name change from Brooklyn ImmunoTherapeutics.